A new way to deliver medicine to help prevent colon cancer
Official title: Microsphere-based formulation of dolcanatide to prevent colon carcinogenesis
Funded at Nous Biosciences INC · NIH-11114059 · Data updated 2026-11-12
This project is developing a special way to deliver a medicine called dolcanatide to help prevent colon cancer, especially for people at higher risk.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Nous Biosciences INC NIH-funded |
| Lab location | 1 site (Doylestown, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $90,723 |
| NIH project number | 5R43CA291267-02 |
| Project ID | NIH-11114059 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients at high risk for colorectal cancer, such as those with inflammatory bowel disease, could potentially benefit from this preventative strategy.
✕Less likely to help
Patients who do not have a risk of colorectal cancer or are already undergoing active treatment for advanced cancer may not directly benefit from this preventative approach.
What this research studies
Colorectal cancer is a serious health concern, particularly for individuals with inflammatory bowel disease. Our bodies naturally have a system, called GC-C signaling, that helps keep the colon healthy, but this system can be disrupted in early stages of cancer. This project aims to create a new, targeted way to deliver a medicine that can restore this important signaling. By using tiny microspheres, the medicine can be released effectively to help maintain colon health and potentially stop cancer from developing.
Why it matters
Potential benefit: If successful, this approach could offer a new oral treatment option to prevent colorectal cancer, especially for those with a higher risk.
How similar studies have gone: Previous work has shown that restoring GC-C signaling can inhibit polyp formation and delay cancer progression in animal models, suggesting promise for this approach.
Where this research is happening
-
Nous Biosciences INC
Doylestown, United States Active
Researchers
- Principal investigator: Shailubhai, Kunwar — Nous Biosciences INC
- Study coordinator: Shailubhai, Kunwar
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.